1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

FDA Stroke Risk Study Suggests No Need To Change COVID-19 Vaccine Administration Strategy

 
• By Brenda Sandburg

But new study finds increased risk of non-hemorrhagic stroke in those receiving high-dose adjuvanted flu vaccines, and another study detects new signal for seizures/convulsions among younger children who received COVID vaccine. Authors say findings warrant more investigations.

Covid-19 vaccine risks
FDA study assesses risk of stroke with mRNA COVID-19 vaccines • Source: Shutterstock

A study co-authored by researchers at the US Food and Drug Administration’s Center for Biologics Evaluation and Research looking at potential safety issues associated with concomitant COVID and influenza vaccine administration does not indicate a need to change strategy around dosing but does recommend more studies on the safety of influenza vaccines. The study did not find any statistically significant association of stroke following administration of COVID-19 mRNA bivalent vaccines in those aged 65 and older but found a small increased risk of non-hemorrhagic stroke in those receiving high-dose adjuvanted flu vaccines.

A preprint version of the study, “Evaluation of Stroke Risk Following COVID-19 mRNA Bivalent Vaccines Among U.S. Adults Aged ≥65...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 
• By Sarah Karlin-Smith

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

New CDER Deputy Director Michael Davis Brings Psychedelic Drug Development Experience

 
• By Sue Sutter

Davis, a former FDA team leader in the Division of Psychiatry Products, rejoins the agency from the Usona Institute, which develops psychedelics. His background aligns with Commissioner Martin Makary’s goal of seeing new treatments approved for post-traumatic stress disorder.

US FDA Acting Drug Center Chief Corrigan-Curay Retiring, Senior Staff Remake Continues

 
• By Derrick Gingery

The news coincides with rumors that Commissioner Martin Makary soon will name a new Center for Drug Evaluation and Research director.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

More from Agency Leadership

US FDA Acting Drug Center Chief Corrigan-Curay Retiring, Senior Staff Remake Continues

 
• By Derrick Gingery

The news coincides with rumors that Commissioner Martin Makary soon will name a new Center for Drug Evaluation and Research director.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

 
• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.